References
- Kelly CA, Saravanan V, Nisar M, et al [2014] Rheumatoid
arthritis-related interstitial lung disease: associations,prognostic
factors and physiological and radiological characteristics-a large
multicentre UK study. Rheumatology (Oxford) 53:1676-1682
- Hyldgaard C, Hilberg O, Pedersen AB, et al [2017] A
population-based cohort study of rheumatoid arthritis associated
interstitial lung disease: comorbidity and mortality. Ann Rheum Dis
76:1700-1706
- Ferna’ndez-Dı’az C, Castaneda S, Melero-Gonza’ lez RB, et al
[2020] Abatacept in interstitial lung disease associated with
rheumatoid arthritis: national multicenter study of 263 patients.
Rheumatology 59(12):3906-3916.
https.//doi.org/10.1093/rheumatology/keaa621(PMID: 33068439)
- Juge PA, Crestani B, Dieude’ P [2020] Recent advances in
rheumatoid arthritis-associated interstitial lung Disease. Curr Opin
Pulm Med 26(5):477-486.
https.//doi.org/10.1097/MCP.0000000000000710(PMID: 32701675)
- Englanda BR, Hershberger D [2020] Management issues in rheumatoid
arthritis-associated interstitial lung disease. Curr Opin Rheumatol
32(3):255-263. https.//doi.org/10.1097/BOR.0000000000000703
- Cassone G, Manfredi A, Vacchi C, et al [2020] Treatment of
rheumatoid arthritis-associated interstitial lung disease: lights and
shadows. J Clin Med 9(4):1082. https.//doi.org/10.3390/jcm9041082
- Yang GX, Lyu L, Wang XH, et al [2019] Systemic treatment with
resveratrol alleviates adjuvant arthritis-interstitial lung disease in
rats via modulation of JAK/STAT/RANKL signaling pathway. Pulm
Pharmacol Ther 56:69-74
- Montero P, Milara J, Roger I, et a l [2021] Role of JAK/STAT in
Interstitial Lung Diseases,Molecular and Cellular Mechanisms. Int J
Mol Sci 22(12):6211. https.//doi.org/10.3390/ijms22126211(PMID:
34207510)
- Vacchi G, Manfredi A, Cassone G, et al [2021] Tofacitinib for the
treatment of severe interstitial lung disease related to rheumatoid
arthritis.Case Rep Med 22, 2021:6652845
- Sendo S, Saegusa J, Yamada H, et al [2019] Tofacitinib facilitates
the expansion of myeloid-derived suppressor cells and ameliorates
interstitial lung disease in SKG mice. Arthritis Res Ther 21(1):184.
https.//doi.org/ 10.1186/s13075-019-1963-2
- Lescoat A, Lelong M, Jeljeli M, et al [2020] Combined
anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on
macrophages in vitro and in vivo: Perspectives for
scleroderma-associated interstitial lung disease. Biochem Pharmacol
178:114103. https.//doi.org/10.1016/j.bcp.2020.114103
- Atardella M, Di Carlo M, Carotti M, et al [2022] Retrospective
study of the efficacy of JAK inhibitors or abatacept on rheumatoid
arthritis-interstitial lung disease. Inflammopharmacology
30(3):705-712. https.//doi.org/ 10.1007/s10787-022-00936-w
- Zhao L, Mu BY, Zhou RW, et al [2019] Iguratimod ameliorates
bleomycin induced alveolar inflammation and pulmonary fibrosis in mice
by suppressing expression of matrix metalloproteinase-9. Int. J.
Rheum. Dis 22 (4) 686-694
- Jiang H, Gao H, Wang Q, et al [2020] Molecular mechanisms and
clinical application of Iguratimod: A review. Biomed Pharmacother 122:
109704
- Han Q, Zheng ZH, Liang Q,et al [2021] Iguratimod reduces B-cell
secretion of immunoglobulin to play a protective role in interstitial
lung disease.Int Immunopharmacol
97(8):107596. https.//doi.org/10.1016/j.intimp.2021.107596.)
- Fujikia Y, Kotania T, Isodab K, et al [2018] Evaluation of
clinical prognostic factors for interstitial pneumonia in anti-MDA5
antibody-positive dermatomyositis patients. MODERN RHEUMATOLOGY
28(1):133-140. https.//doi.org/10.1080/14397595.2017.1318468
- Kodera K, Tsutsumi T, Oka Y, et al [2021]Two cases of rheumatoid
arthritis complicated by organising pneumonia successfully treated
with tofacitinib therapy. Mod Rheumatol Case Rep
5(2):218-225. https.//doi.org/10.1080/24725625.2021.1899372
- Vacchi G, Manfredi A, Cassone G, et al [2021] Tofacitinib for the
treatment of severe interstitial lung disease related to rheumatoid
arthritis.Case Rep Med 22, 2021:6652845
- Tanaka Y, Maeshima K, Yamaoka K [2012] In vitro and in vivo
analysis of JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis
71(Suppl 2):i70-174. https.//doi.org/10.1136/annrheumdis-2011-200595
- Wang WX, Bhattacharyya S, Marangoni RG, et al [2020] The JAK/STAT
pathway is activated in systemic sclerosis and is effectively targeted
by tofacitinib. J Scleroderma Relat Disord 5(1):40-50.
https.//doi.org/ 10.1177/2397198319865367.
- Kurasawa K, Arai S, Namiki Y, et al [2018] Tofacitinib for
refractory interstitial lung diseases in anti-melanoma
differentiation-associated 5 gene antibody-positive dermatomyositis.
Rheumatology (Oxford) 57(12):2114-2119
- Wu YX, Sun Y, Ye YP, et al [2017] Iguratimod prevents ovariectomy
induced bone loss and suppresses osteoclast ogenesis via inhibition of
peroxisome proliferator activated receptor gamma. Mol. Med. Rep 16 (6)
8200-8208